Prediction and preliminary screening of HLA-A*0201-restricted epitope peptides of human GPC3.
In response to the limited therapeutic option for hepatocellular carcinoma (HCC), immunotherapy as a promising approach points out a new direction to the cure of tumours through specific recognition and elimination of tumour cells by the immunity-enhanced autologous immunocytes of patients. Few effective tumour antigens, however, are alternative in addition to alpha fetoprotein or tumour cell lysates. Recent studies have demonstrated that glypican-3 (GPC3) is not only a promising diagnostic marker, but also ideal therapeutic target to HCC. In this study, potential HLA-A*0201 GPC3 peptides were screened with three epitope prediction software, the binding affinity of 13 predicted epitopes with high scores was determined by T2 cells binding assay and four optimal epitopes were identified. This is the first study in which the optimal HLA-A*0201 GPC3 epitopes were screened from a large number of candidates predicted by three software. The optimized HLA-A*0201 GPC3 peptides will provide new epitope candidates for HCC immunotherapy.
Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.|Institute of Biomedical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
P
P
Hu
Institute of Biomedical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Z
Z
Wei
Institute of Biomedical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
R
R
Li
Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
D
D
Wu
Institute of Biomedical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China.|Department of Infectious Diseases, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Z
Z
Meng
D000951:Antigens, Neoplasm; D006528:Carcinoma, Hepatocellular / Q000276:immunology* / Q000628:therapy; D000939:Epitopes / Q000276:immunology; D053673:Glypicans / Q000276:immunology* / Q000627:therapeutic use; D015789:HLA-A2 Antigen / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000276:immunology* / Q000628:therapy; D010455:Peptides / Q000276:immunology / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000951:Antigens, Neoplasm; D000939:Epitopes; C105937:GPC3 protein, human; D053673:Glypicans; C435939:HLA-A*02:01 antigen; D015789:HLA-A2 Antigen; D010455:Peptides